Teva’s two asthma treatments for patients older than 12 has been approved by the US Food and Drug Administration (FDA).
The two products are AirDuo and ArmonAir and both include drug delivered by breath-activated, multi-dose dry powder inhaler (MDPI) RespiClick, which is also used with other Teva’s breathing product.
AirDuo RespiClick is a fixed dose combination product containing the same active ingredients as GlaxoSmithKline’s Advair, while ArmonAirTM RespiClick, an inhaled corticosteroid (ICS), has the same active ingredient as GSK’s Flovent.
“As a company on the forefront of developing inhaler technologies for people living with asthma, we are very pleased to now have two additional RespiClick-delivered medicines approved for adolescent and adult patients in the U.S.,” said Michael Hayden, MD, PhD, President of Global R&D and Chief Scientific Officer at Teva.
Rob Koremans, M.D., President and CEO of Global Specialty Medicines at Teva said, “With these approvals, we now integrate both fixed dose combination and monotherapy into our core, breath-activated RespiClick device.”
Teva said that both products (by prescription) should be available in the U.S. later in 2017.